Notice2025-10854
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research for the benefit of the public health.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 114 (Monday, June 16, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 114 (Monday, June 16, 2025)]
[Notices]
[Pages 25344-25345]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-10854]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research for the
benefit of the public health.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the licensing contact Michael Shmilovich, Esq.; 301-435-
5019; <a href="/cdn-cgi/l/email-protection#96e5fefbfffaf9e0fbd6f8fffeb8f1f9e0"><span class="__cf_email__" data-cfemail="087b60656164677e6548666160266f677e">[email protected]</span></a>, at the National Heart, Lung, and Blood, Office
of Technology Transfer and Development, 31 Center Drive, Room 4A25,
MSC2479, Bethesda, MD 20892-2479. A signed Confidential Disclosure
Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404. Technology description follows.
Reversibly Photo-Switchable Fluorescent Proteins for Long-Term Imaging
of Live Specimen
Available for research uses, collaboration, and further development
are non-cytotoxic reversibly photo-switchable fluorescent mutant
proteins that may be locked in a state of high brightness, which may be
useful for long-term biomedical applications at routine laser power
intensity. Additionally, these proteins offer quick self-recovery of
peak fluorescence, which may be useful for imaging of rapid cellular
processes.
Inventors
<bullet> Vitaly Boyko, Ph.D. (NIBIB)
<bullet> George Patterson, Ph.D. (NIBIB)
<bullet> Md Abdul Kader Sagar, Ph.D. (NIBIB)
Potential Applications
<bullet> Long-term imaging of live specimen, including light-sensitive
specimen
<bullet> Probe for high-throughput screening applications
<bullet> Fluorescent marker in biomedical screening protocols
[[Page 25345]]
<bullet> Diagnostic tool for cytotoxicity or component of diagnostic
kit that utilizes fluorescent proteins.
Licensable Materials
<bullet> The nucleotide sequences of fluorescent protein
<bullet> Fusion construct to LC3A autophagy marker protein or
mitochondria targeted peptide.
Dated: June 10, 2025.
Michael A. Shmilovich,
Acting Director, National Heart, Lung, and Blood Institute, Office of
Technology Transfer and Development.
[FR Doc. 2025-10854 Filed 6-13-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.